This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.
Clinical diagnosis of VSAA/SAA.
Age ≥65 years.
Completion of all screening assessments.
Must be able to swallow tablets.
Clonal cytogenetic abnormalities (excluding isolated -Y or +8).
Prior treatment with ATG/high-dose cyclophosphamide.
Prior cyclosporine/tacrolimus use >12 months.
Prior TPO-RA therapy >3 months.